Navigation Links
China Medicine Announces Solid First Quarter 2008 Results
Date:5/12/2008

(1,110,151)

Advances to suppliers (662,079) (761,889)

Other current assets (79,904) (44,544)

Change in operating liabilities

Accounts payable, trade (30,774) 46,475

Other payables and accrued liabilities (49,957) (5,688)

Customer deposits (54,499) 54,531

Taxes payable (142,540) 36,802

Net cash used in operating

activities (1,142,167) (871,460)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of equipment (4,490) (35,399)

Purchase of intangible asset - (129,010)

Net cash used in investing

activities (4,490) (164,409)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercise of warrants

and options 362,500 2,838,062

Net cash provided by financing

activities 362,500 2,838,062

EFFECT OF EXCHANGE RATE ON CASH 193,444 138,282

INCREASE (DECREASE) IN CASH (590,713) 1,940,475

CASH, beginning of period 5,767,774 371,480

CASH, end of period $5,177,061 $2,311,955

Company Contact: Investor Relations Contact:

Ms. Huizhen Yu Mr. Crocker Coulson

Chief Financial Officer President

China Medicine Corp CCG Elite Investor Relations

Tel: +86-20-8739-1718 Tel: +1-646-213-1915 (NY Office)

E-mail: konzern08@163.com
'/>"/>

SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
2. China-Biotics, Inc. Completes Foundation for Its New Plant
3. Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China
4. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
5. China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
6. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
7. DuPont Partnering with China to Increase Farm Productivity
8. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
9. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
10. Syngenta To Build Major Global Biotech Research Center in Beijing, China
11. American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... Israel , September 2, 2015 ... the intent of the National Institute of Allergy and Infectious ... (NIH) within the Department of Health and Human Services (HHS), ... in the United States in the ... universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... Oramed Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... Executive Officer, Mr. Nadav,Kidron, will be giving a company ... at New York City,s Palace Hotel on November,11. Mr. ... in the Kennedy II,Ballroom, located on the 4th floor ...
... ROCKVILLE, Md., Oct. 30 Vanda Pharmaceuticals,Inc. (Nasdaq: ... the development,and commercialization of clinical-stage product candidates for ... results,for the third quarter ended September 30, 2008., ... in the third,quarter of 2008 of $3.8 million, ...
... STE ) today announced financial results for its fiscal ... quarter revenues,increased 10% to $323.1 million compared with $295.0 ... strong growth in all three business,segments. Fiscal 2009 second ... share, compared with net income of $16.0 million, or ...
Cached Biology Technology:Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC) 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 3Vanda Pharmaceuticals Reports Third Quarter 2008 Results 4Vanda Pharmaceuticals Reports Third Quarter 2008 Results 5Vanda Pharmaceuticals Reports Third Quarter 2008 Results 6Vanda Pharmaceuticals Reports Third Quarter 2008 Results 7Vanda Pharmaceuticals Reports Third Quarter 2008 Results 8Vanda Pharmaceuticals Reports Third Quarter 2008 Results 9Vanda Pharmaceuticals Reports Third Quarter 2008 Results 10STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 2STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 3STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 4STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 5STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 6STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 7STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 8STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 9STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 10STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 11
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/11/2015)... 2015 Today, ZUK announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1155 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... prominent smartphone manufacturer in China ... FPC1 155 for Z1 , ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... release is available in French . ... have inherited conditions that leave them unable to process vitamin ... problems, including developmental delay, psychosis, stroke and dementia. An international ... vitamin B12 deficiency by identifying a gene that is vital ...
... used as weapons is truly dreadful, but there is plenty ... ancient times. * Bioterrorism, as it is dubbed, ... a safer place against a myriad of old scourges both ... to uncork a nasty cloud of germs. The ...
... oven technology that most people use to heat up leftover ... industry, providing a new way to make thin-film photovoltaic products ... Oregon State University have for the first time developed a ... zinc tin sulfide, a promising solar cell compound that is ...
Cached Biology News:Vitamin B12 deficiency: Tracking the genetic causes 2Boston subway system to be used to test new sensors for biological agents 2Microwave ovens may help produce lower cost solar energy technology 2
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... automated bioresearch: Developed for a wide ... on decades of experience in Luminescence ... bioresearch • Holographic gratings for reduced ... ease-of-use • Pulsed Xenon lamp reduces ...
... The Precision XS uniquely combines a ... head and an 8-channel bulk reagent dispenser ... addition to transfers using disposable pipette tips, ... resistant bulk reagent dispenser is available for ...
... automated bioresearch: Developed for a wide ... on decades of experience in Luminescence ... bioresearch • Holographic gratings for reduced ... ease-of-use • Pulsed Xenon lamp reduces ...
Biology Products: